Frontiers in Immunology (Mar 2022)

RETRACTED: Dysregulation of Survivin-Targeting microRNAs in Autoimmune Diseases: New Perspectives for Novel Therapies

  • Navid Shomali,
  • Navid Shomali,
  • Navid Shomali,
  • Marwah Suliman Maashi,
  • Behzad Baradaran,
  • Behzad Baradaran,
  • Amin Daei Sorkhabi,
  • Aila Sarkesh,
  • Hamed Mohammadi,
  • Hamed Mohammadi,
  • Maryam Hemmatzadeh,
  • Faroogh Marofi,
  • Siamak Sandoghchian Shotorbani,
  • Siamak Sandoghchian Shotorbani,
  • Mostafa Jarahian

DOI
https://doi.org/10.3389/fimmu.2022.839945
Journal volume & issue
Vol. 13

Abstract

Read online

It has been well established that the etiopathogenesis of diverse autoimmune diseases is rooted in the autoreactive immune cells’ excessively proliferative state and impaired apoptotic machinery. Survivin is an anti-apoptotic and mitotic factor that has sparked a considerable research interest in this field. Survivin overexpression has been shown to contribute significantly to the development of autoimmune diseases via autoreactive immune cell overproliferation and apoptotic dysregulation. Several microRNAs (miRNAs/miRs) have been discovered to be involved in survivin regulation, rendering the survivin-miRNA axis a perspective target for autoimmune disease therapy. In this review, we discuss the role of survivin as an immune regulator and a highly implicated protein in the pathogenesis of autoimmune diseases, the significance of survivin-targeting miRNAs in autoimmunity, and the feasibility of targeting the survivin-miRNA axis as a promising therapeutic option for autoimmune diseases.

Keywords